Form 4: IGMS Merger Completes, Shares Converted to Cash & CVRs

IGM Biosciences, Inc. completed its merger with Concentra Biosciences, converting all outstanding shares into cash and contingent value rights.

Summary

• IGM Biosciences, Inc. completed its merger with Concentra Biosciences, LLC on August 14, 2025.
• The Company is now a wholly owned subsidiary of Concentra Biosciences, LLC.
• All outstanding shares of Common Stock and Non-Voting Common Stock were cancelled.
• Shareholders received $1.247 in cash per share.
• Shareholders also received one contractual contingent value right (CVR) per share, subject to the terms and conditions of a Contingent Value Rights Agreement.
• Jakob Haldor Topsoe, a Director and 10% Owner, disposed of 91,712 directly held Common Stock shares.
• Topsoe Holding A/S, an entity through which Jakob Haldor Topsoe indirectly held shares, disposed of 10,400,564 Common Stock shares and 5,044,295 Non-Voting Common Stock shares.
• Following the merger, Jakob Haldor Topsoe and Topsoe Holding A/S hold 0 shares in IGM Biosciences, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The merger completed as expected, providing immediate cash value and potential future value via CVRs, which offers some upside. However, shareholders lose direct equity ownership, which can be seen as a negative for long-term growth participation.

Positives

• The merger transaction has successfully completed, providing liquidity to shareholders.
• Shareholders received a cash payment of $1.247 per share.
• The inclusion of a Contingent Value Right (CVR) provides potential for future additional value based on specific terms.

Negatives

• All outstanding shares of IGM Biosciences, Inc. Common Stock and Non-Voting Common Stock were cancelled, meaning shareholders no longer hold equity in the company.
• The company is now a wholly owned subsidiary, removing its public trading status.
• The value of the CVR is contingent and not guaranteed, introducing uncertainty regarding future payments.

Risks

• The value of the Contingent Value Right (CVR) is uncertain and dependent on future events or performance as per the Contingent Value Rights Agreement.
• Shareholders no longer have direct equity ownership in IGM Biosciences, Inc. and thus no longer participate in its future growth or profitability beyond the CVR terms.

Future Outlook

The future value for former shareholders is tied to the Contingent Value Rights (CVRs), which provide potential for additional payments based on the terms and conditions of a separate Contingent Value Rights Agreement.

Industry Context

This merger signifies a consolidation event within the biotechnology or pharmaceutical sector, where smaller companies are acquired by larger entities, often for their pipeline assets or technology. Such transactions are common strategies for larger companies to expand their portfolios and for smaller companies to gain resources or provide liquidity to shareholders.

Related Party Transactions

• The reporting person, Jakob Haldor Topsoe, is a Director and 10% Owner of IGM Biosciences, Inc. The shares were indirectly held by Topsoe Holding A/S, where Jakob Haldor Topsoe and other board members may be deemed to share voting and investment power. This indicates a transaction involving a significant related party.

Stakeholder Impact

• Shareholders: Received cash and CVRs in exchange for their shares, losing direct equity ownership in the company.
• Employees: The company is now a wholly owned subsidiary, which could lead to integration changes, though not explicitly stated.
• Creditors: No direct impact mentioned, but the change in ownership structure could affect future creditworthiness or covenants.

Next Steps

• Realization of value from the Contingent Value Rights (CVRs) based on the terms of the Contingent Value Rights Agreement.

Key Dates

Recommendation

The merger has completed, and shares have been converted to cash and CVRs. There is no longer an active stock to trade for IGM Biosciences, Inc. The 'hold' recommendation applies to the CVRs, as their value is contingent and future realization is uncertain, but they represent potential future upside. For the stock itself, it's effectively 'NA' as it's no longer publicly traded.

Keywords

IGM Biosciences, IGMS, Merger, Acquisition, SEC Form 4, Contingent Value Right, CVR, Share Cancellation, Biotechnology, Concentra Biosciences